Concepedia

Author

Danny Sugimoto

Novo Nordisk (Denmark)ORCID

Also Known As

D Sugimoto, D. Sugimoto, DANNY SUGIMOTO, Danny H. Sugimoto, Danny Sugimoto, Gigi Lefebvre, I. Lager, K Sugawara, Mashrur Islam Majumder, May-Yin Suen

41

Publications

2K

Citations

15

H-Index

23

Concepts

All Affiliations

Novo Nordisk (Denmark)University of PennsylvaniaUniversity of Alabama at BirminghamBoehringer Ingelheim (Germany)Novo Nordisk (United States)
DS

About

Danny Sugimoto is an author at Novo Nordisk (Denmark) specializing in pharmacotherapy, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

299

2

Diabetes

3

3

133

3

Nephrology

2

2

166

4

Public Health

1

1

99

5

Nutrition

1

1

99

Danny Sugimoto

×

15

Publications

1.5K

Citations

13

H-Index

YearCitations

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

Helena W. Rodbard, Ildiko Lingvay, John H. Reed,

The Journal of Clinical Endocrinology & Metabolism

2018

353

Triple Therapy in Type 2 Diabetes

Julio Rosenstock, Danny Sugimoto, Poul Strange,

Diabetes Care

2006

236

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial

Thomas A. Wadden, Jena Shaw Tronieri, Danny Sugimoto,

Obesity

2020

183

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

W. Timothy Garvey, Andreas L. Birkenfeld, Dror Dicker,

Diabetes Care

2020

170

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani,

The Lancet

2023

151

A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study

MH Davidson, LD Dugan, J Burns,

American Journal of Clinical Nutrition

1996

99

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Erin A. Bohula, Benjamin M. Scirica, Silvio E. Inzucchi,

The Lancet

2018

94

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne,

The Lancet Diabetes & Endocrinology

2023

88

Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5)

Robin Conway, Helena W. Rodbard, Ildiko Lingvay,

Canadian Journal of Diabetes

2016

25

Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial

Jena Shaw Tronieri, Anthony N. Fabricatore, Thomas A. Wadden,

Obesity Facts

2020

21

Page 1